BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, April 10, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Regulatory actions for Feb. 10, 2021

Feb. 10, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Adaptive Phage, AIM Immunetech, Astrazeneca, Biontech, Eli Lilly, I-Mab, Merck, Panbela, Pfizer, RDIF, Regeneron, Sanifit, Sanofi, Takeda, Vico.
Read More

In the clinic for Feb. 10, 2021

Feb. 10, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Algernon, Basilea, Celon, Galapagos, Galecto, Gamida, Gemini, Genfit, Gilead, Infant Bacterial, Protalix, Regulus, Tessa, Yumanity.
Read More
Celltrion-Regkirona-2-9

Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

Feb. 9, 2021
By Gina Lee
HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal antibody, Regkirona (regdanvimab, also known as CT-P59), in South Korea. It’s the first company to receive approval for a COVID-19 antibody treatment developed in South Korea, a MFDS spokesman told BioWorld.
Read More

Regulatory actions for Feb. 9, 2021

Feb. 9, 2021
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ava, Bactiguard, Nyxoah, Soundbite Medical.
Read More

Other news to note for Feb. 9, 2021

Feb. 9, 2021
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Beyond Medical Technologies, Biodesix, Biotelemetry, Canary Health Technologies, Foxsemicon Integrated Technologies, GE Healthcare, Kayan Health, Predictiv Care, Prophase Labs, Royal Philips, Smartbreast, SyntheticMR, Tissium, Trisalus, United Imaging, Zavation Medical Products.
Read More

In the clinic for Feb. 9, 2021

Feb. 9, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Biodesix, Foundation Medicine, Medtronic.
Read More
WHO COVID-19 origins press conference

Intermediary host species likely introduced SARS-CoV-2 virus, says WHO

Feb. 9, 2021
By Nuala Moran
LONDON – The World Health Organization’s (WHO) mission to Wuhan has rejected accidental laboratory escape as the source of the SARS-CoV-2 pandemic, but failed to uncover satisfactory evidence of its exact origin.
Read More

Regulatory actions for Feb. 9, 2021

Feb. 9, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amarin, Astrazeneca, Bausch Health, Brainstorm Cell, BMS, China Oncology Focus, Edding, Immunomet, Navidea, RDIF, Sorrento, Triastek.
Read More

In the clinic for Feb. 9, 2021

Feb. 9, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Agenus, Amicus, BMS, Brooklyn Immunotherapeutics, Cardior, Curis, Cyclo, Evolve, Exelixis, Heat, Innate, Innovent, Ipsen, Janssen, Kalvista, Medigene, Melt, Neurorx, Opiant, Orchard, Paxmedica, Regenxbio, Sumitomo, Taiga, Trefoil, Turn.
Read More
U.S. White House

White House vows to invoke DPA to respond to pandemic, including more at-home tests

Feb. 8, 2021
By Mark McCarty
The Biden administration said it will use the U.S. Defense Production Act to grapple with the COVID-19 pandemic in a plan that includes a large increase in vaccine purchases. Also on tap is an increase in production of at-home test by six companies in addition to Ellume Ltd., of Perth, Australia, which will ship more than 8 million of their tests to the U.S. by the end of the year.
Read More
Previous 1 2 … 285 286 287 288 289 290 291 292 293 … 551 552 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 9, 2026.
  • Hengrui discovers new Nav1.8 blockers

    BioWorld Science
    Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
  • Cancer and blood cells

    Hematopoietic stem cell research points to leukemia’s early roots

    BioWorld Science
    Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • Brain with clock hands, day and night background

    Lilly shifts from obesity to narcolepsy with $7.8B Centessa buy

    BioWorld
    Eli Lilly and Co. plans to buy Centessa Pharmaceuticals plc for $6.3 billion in up-front cash and another potential $1.5 billion through contingent value rights,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing